ScreenerHero

NNVCNanoViricides, Inc.

AMEX · US · Healthcare · Biotechnology · nanoviricides.com
1.330USD-0.75%Mkt Cap: 33.91M $P/E: —

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap33.91M $
Enterprise Value25.58M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-9.47M $
Revenue/Share—
Last Price1.330 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS6300873022
Valuation
P/E (Trailing)—
P/E (Forward)-3.80
PEG—
EV/EBITDA-3.36
EV/Revenue—
P/S—
P/B3.14
EPS (TTM)-0.44
EPS (Forward)-0.35
52W Range
0.850035% of range2.230
52W High2.230 USD
52W Low0.8500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-125.93%
ROA-107.29%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.48M $
CapEx (TTM)56.96K $
FCF Margin—
FCF Yield-12.95%
Net Debt-3.21M $
Net Debt/EBITDA0.42
Balance Sheet
Debt/Equity—
Current Ratio3.17
Quick Ratio3.02
Book Value/Sh0.4230 USD
Cash/Share0.1480 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 24, 2019
Splits
Last Split1:20
Split DateSep 24, 2019
Analyst Consensus
Rating—
Target (Mean)6.000 USD
Upside (mean)+351.1%
Target Range6.000 USD – 6.000 USD
# Analysts2
Ownership
Shares Out.25.50M
Float21.08M
Insiders2.36%
Institutions9.34%
Short Interest
Short Ratio1.6d
Short % Float2.40%
Short % Out.2.34%
Shares Short596.85K
Short (prev mo.)886.11K
Technical
SMA 501.460 (-8.9%)
SMA 2001.290 (+3.1%)
Beta1.69
S&P 52W Chg19.18%
Avg Vol (30d)350.02K
Avg Vol (10d)308.01K
Technical Indicators
RSI (14)38.3
MACD-0.0498
MACD Signal-0.0341
MACD Hist.-0.0157
BB Upper1.626 USD
BB Middle1.450 USD
BB Lower1.273 USD
BB Width24.30%
ATR (14)0.0972 USD
Vol Ratio (20d)0.78x